Product Information
ABILIFY MAINTENA ER 300 MG SYR is a brand product labeled by Otsuka America Pharmaceutical Inc., priced at $2137.3167 per EA under NDC 59148004580. Its NADAC has been published 519 times since Jul 20, 2016.
The High Outlier badge above means this manufacturer's average price in the aripiprazole market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Manufacturer
Otsuka America Pharmaceutical Inc.NDC
59148004580
Classification
Brand
Dosage Form
KIT
Last Updated
6/17/2026
Approval Type
New Drug (NDA)
FDA Application
NDA202971On Market Since
10/8/2014
Price Statistics
The NADAC for ABILIFY MAINTENA ER 300 MG SYR has been published 519 times since Jul 20, 2016, and over the history we have for it it has risen 65.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2137.3167 per EA |
|---|---|
| All-time high | $2142.7480 (May 13, 2026) |
| All-time low | $1289.9827 (Jul 20, 2016) |
| 52-week high | $2142.7480 |
| 52-week low | $2080.0578 |
| Median price | $1714.3857 |
| Average price | $1744.1444 |
| Largest weekly change | +6.9% (Jan 26, 2022) |
| Weeks tracked | 519 |
| Tracking since | Jul 20, 2016 |
Generic Alternatives
The matcher finds 1 NADAC-published product sharing this drug's active ingredient, strength, and dosage form across 1 manufacturer (up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of ABILIFY MAINTENA ER 300 MG SYR?
The current National Average Drug Acquisition Cost (NADAC) for ABILIFY MAINTENA ER 300 MG SYR, manufactured by Otsuka America Pharmaceutical Inc., is $2137.3167 per EA (NDC 59148004580), effective Jun 24, 2026.
How has the price of ABILIFY MAINTENA ER 300 MG SYR changed over time?
Over the history we have for it, the NADAC for ABILIFY MAINTENA ER 300 MG SYR has risen 65.7%. It has been tracked across 519 weekly CMS publications since Jul 20, 2016.
What are the highest and lowest recorded NADAC prices for ABILIFY MAINTENA ER 300 MG SYR?
Since Jul 20, 2016, the NADAC for ABILIFY MAINTENA ER 300 MG SYR has ranged from a low of $1289.9827 (Jul 20, 2016) to a high of $2142.7480 (May 13, 2026), with a median of $1714.3857 per EA.
Are there cheaper alternatives to ABILIFY MAINTENA ER 300 MG SYR?
1 NADAC-published product shares the same active ingredient, strength, and dosage form as ABILIFY MAINTENA ER 300 MG SYR, but none are currently priced below it.
Who manufactures ABILIFY MAINTENA ER 300 MG SYR?
ABILIFY MAINTENA ER 300 MG SYR (NDC 59148004580) is labeled by Otsuka America Pharmaceutical Inc., and CMS classifies it as a brand product.
Related Drugs
Same classification